Showing posts with label Herceptin. Show all posts
Showing posts with label Herceptin. Show all posts

Saturday, March 6, 2010

Perspectives about cancer from a student blogger

This is a guest post by David Reis. If you're interested in submitting a guest post, please contact me.

What is cancer?  How does it develop and what treatments will the future offer?

First it’s important to note that cancer is made out of cells from your own body that have, so to speak, decided to revolt and do their own thing.  Our body naturally needs to replace itself as you wear out, and some tissues are constantly growing.  On a daily basis, we make hundreds of billions of new blood cells for instance.

Problems arise when the body loses its natural balance.  A breast cell, say, that only is supposed to divide 10 times undergoes  a mutation that removes some of the checkpoints.  But that alone isn’t usually enough.  For cancer to develop, typically several things have to go wrong. So the breast cell loses the restriction that prevents it from dividing more than 10 times – and loses the system that tells it to commit suicide (or apoptosis) if it grows too much.  The result could be a tumor.

Still, not all cancers lead to disease.  The breast cell can grow a little bit then stop.  Or it can start growing abnormally but trigger the body’s immune response which either wipes it out or stops it from growing further.

Sunday, May 24, 2009

Novel Cancer Biomarkers, Oncogenes, and Targeted Therapies



Since I graduated from medical school (many years ago), we have discovered so many new cancer biomarkers and oncogenes. The world of genomics has really taken off! As I think about the future of medicine, I often wonder about how many more biomarkers and oncogenes we will discover. How many new drugs will get developed to specifically target the overexpression of specific oncogenes? Human genetics and molecular biology are becoming more fascinating topics because we now have the ability to engineer drugs that target specific genes and gene products.

Here are a few examples of some of the newer areas of cancer research:
  • DNA Methylation Biomarker, Septin 9, (Colorectal Cancer)
  • Non-codingRNA (microRNA)
  • Metabolomics-derived Biochemical Markers (Prostate Cancer)
We all know about BRCA1 and BRCA2. We also know that HER2 overexpression can be targeted by an anti-HER2 humanized monoclonal antibody (called trastuzumab or Herceptin). The topic of personalized medicine has been gaining tremendous traction, especially in the oncology world. What if there was a way to prevent hereditary cancers? If we can identify ways to target the specific gene (or genes) that are causing cancer, then we might be able to prevent those malignancies. Advances in drug development have led to many biologic agents (targeted therapies) that act on specific pathways like VEGF (vascular endothelial growth factor) and block the formation of new blood vessels. You've probably heard of bevacizumab or Avastin, which is a VEGF-inhibitor.

Speaking of biologic drugs, I still remember when the first tyrosine kinase inhibitor (TKI) came out. Remember when Gleevec (imatinib) came out? TKIs have now evolved into agents that target multiple different tyrosine kinase pathways and even inhibit EGFR (epidermal growth factor receptor). We now have nilotinib (Tasigna), dasatinib (Sprycel), erlotinib (Tarceva), gefitinib (Iressa), and several more coming. How do medical students keep up with all these drugs? Students today are even learning about new compounds like histone deacetylase inhibitors (HDAC inhibitors or HDIs). We've certainly come a long way in the world of cancer biomarkers, oncogenes, and targeted therapies. What will the future look like as we learn how to target these biomarkers and oncogenes? Image source: